Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes– Associated HLA Genotypes in Women With Gestational Diabetes Mellitus

Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes– Associated HLA Genotypes in Women With Gestational Diabetes Mellitus Jianping Weng , MD, PHD 1 , Magnus Ekelund , MD 1 , Markku Lehto , PHD 1 , Haiyan Li , BM 1 , Göran Ekberg , MD 1 , Anders Frid , MD, PHD 2 , Anders Åberg , MD, PHD...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 25; no. 1; pp. 68 - 71
Main Authors Weng, Jianping, Ekelund, Magnus, Lehto, Markku, Li, Haiyan, Ekberg, Göran, Frid, Anders, Åberg, Anders, Groop, Leif C., Berntorp, Kerstin
Format Journal Article
LanguageEnglish
Published Alexandria, VA American Diabetes Association 01.01.2002
Subjects
Online AccessGet full text
ISSN0149-5992
1935-5548
1935-5548
DOI10.2337/diacare.25.1.68

Cover

More Information
Summary:Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes– Associated HLA Genotypes in Women With Gestational Diabetes Mellitus Jianping Weng , MD, PHD 1 , Magnus Ekelund , MD 1 , Markku Lehto , PHD 1 , Haiyan Li , BM 1 , Göran Ekberg , MD 1 , Anders Frid , MD, PHD 2 , Anders Åberg , MD, PHD 3 , Leif C. Groop , MD, PHD 1 and Kerstin Berntorp , MD, PHD 1 1 Department of Endocrinology, Malmö University Hospital, Lund University, Malmö, Sweden 2 Department of Internal Medicine, Lund University Hospital, Lund University, Lund, Sweden 3 Department of Obstetrics and Gynecology, Lund University Hospital, Lund University, Lund, Sweden Abstract OBJECTIVE —To investigate whether genetic susceptibility to type 1 diabetes or maturity-onset diabetes of the young (MODY) increases susceptibility to gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS —We studied mutations in MODY1–4 genes, the presence of GAD antibodies, and HLA DQB1 risk genotypes in 66 Swedish women with GDM and a family history of diabetes. An oral glucose tolerance test was repeated in 46 women at 1 year postpartum. RESULTS —There was no increase in type 1 diabetes–associated HLA-DQB1 alleles or GAD antibodies when compared with a group of type 2 diabetic patients ( n = 82) or healthy control subjects ( n = 86). Mutations in known MODY genes were identified in 3 of the 66 subjects (1 MODY2, 1 MODY3, and 1 MODY4). Of the 46 GDM subjects, 2 had diabetes (4%) and 17 had impaired glucose tolerance (IGT) (37%) at 1 year postpartum. Of the two subjects who developed manifest diabetes, one carried a MODY3 mutation (A203H in the hepatocyte nuclear factor-1α gene). There was no increase in high-risk HLA alleles or GAD antibodies in the women who had manifest diabetes or IGT at 1 year postpartum. CONCLUSIONS —MODY mutations but not autoimmunity contribute to GDM in Swedish women with a family history of diabetes and increase the risk of subsequent diabetes. GCK, glucokinase GDM, gestational diabetes mellitus HNF, hepatocyte nuclear factor IGT, impaired glucose tolerance IPF1, insulin promoter factor-1 MODY, maturity-onset diabetes of the young NGT, normal glucose tolerance OGTT, oral glucose tolerance test PCR, polymerase chain reaction SSCP, single-strand conformation polymorphism Footnotes Address correspondence and reprint requests to Dr. Magnus Ekelund, Department of Endocrinology, Malmö University Hospital, S-205 02, Malmö, Sweden. E-mail address: magnus.ekelund{at}skane.se . Received for publication 9 May 2001 and accepted in revised form 9 October 2001. J.W. is currently affiliated with the Department of Endocrinology, the First Affiliated Hospital of SUMS, Guangzhou, China. M.L. is currently affiliated with the Department of Molecular Medicine, Intracellular Transport Unit, National Public Health Institute, Helsinki, Finland. J.W. and M.E. contributed equally to this work. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0149-5992
1935-5548
1935-5548
DOI:10.2337/diacare.25.1.68